Current cardiology reports · 2025
Optimizing Care for Cardiovascular-Kidney-Metabolic Syndrome: Leveraging Implementation Science in the Path Toward Pharmacoequity.
СтатьяОбзорНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Longley Regina M, Katzenstein Cecilia, Mohottige Dinushika
Аннотация
PURPOSE OF REVIEW: Overview the current landscape of pharmacoequity in cardiovascular-kidney-metabolic (CKM) syndrome.
RECENT FINDINGS: CKM syndrome is a key driver of the significant morbidity and mortality associated with cardiovascular disease, and poses a significant threat to public health. Despite a growing armamentarium of evidence-based therapies for the prevention and management of CKM syndrome, access to these treatments remains unequal. For instance, gender, race, and ethnicity-based disparities have been noted in use of first-line, guideline-directed, disease-modifying drugs. Barriers to pharmacoequity in CKM including multimorbidity/polypharmacy, low awareness, clinical inertia, cost, pharmacy inaccessibility, unequal socio-contextual factors, and fragmented care require urgent attention including equity-promoting policy. Individual- and system-level barriers to pharmacoequity in CKM syndrome impede optimal CKM management, particularly among minoritized populations. We describe how a multifaceted, multi-level approach to CKM equity including interdisciplinary care and clinical decision support tools designed from an implementation science lens may help combat these inequities.
RECENT FINDINGS: CKM syndrome is a key driver of the significant morbidity and mortality associated with cardiovascular disease, and poses a significant threat to public health. Despite a growing armamentarium of evidence-based therapies for the prevention and management of CKM syndrome, access to these treatments remains unequal. For instance, gender, race, and ethnicity-based disparities have been noted in use of first-line, guideline-directed, disease-modifying drugs. Barriers to pharmacoequity in CKM including multimorbidity/polypharmacy, low awareness, clinical inertia, cost, pharmacy inaccessibility, unequal socio-contextual factors, and fragmented care require urgent attention including equity-promoting policy. Individual- and system-level barriers to pharmacoequity in CKM syndrome impede optimal CKM management, particularly among minoritized populations. We describe how a multifaceted, multi-level approach to CKM equity including interdisciplinary care and clinical decision support tools designed from an implementation science lens may help combat these inequities.